<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03265288</url>
  </required_header>
  <id_info>
    <org_study_id>LAU-14-01</org_study_id>
    <nct_id>NCT03265288</nct_id>
  </id_info>
  <brief_title>Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults</brief_title>
  <acronym>APPLAUD</acronym>
  <official_title>APPLAUD: A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Cystic Fibrosis in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laurent Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laurent Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the
      safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the
      safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.
      All patients will remain on their CF standard-of-care treatments over the trial duration.

      The goal for the treatment with LAU-7b in CF is to preserve lung function by reducing the
      persistent inflammation in the lung and to improve its capacity to defend against resistant
      bacteria such as Pseudomonas aeruginosa.

      The treatment regimen will consist of 6 consecutive &quot;dosing cycles&quot; of 21 days each, spaced
      by study drug-free periods of 7 days. A total of 136 eligible adult patients with CF will be
      randomized to receive 300 mg LAU-7b or placebo in a 1:1 ratio. The participation in the study
      will last about 7 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, parallel groups and placebo-controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients will be randomly assigned to take either the active drug (fenretinide capsule) or a matching inactive placebo (inactive capsule).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in percent predicted forced expiratory volume in 1 second (FEV1%)</measure>
    <time_frame>From baseline to 24 weeks</time_frame>
    <description>Standardized, serial FEV1 measurements will be performed during the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of LAU-7b will be assessed by the incidence of treatment emergent adverse events compared to placebo</measure>
    <time_frame>From Baseline to 28 weeks</time_frame>
    <description>This will be assessed through serial assessments and ad-hoc assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving normalization of the arachidonic acid, docosahexaenoic acid and their ratio in phospholipids</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>This will be assessed through serial blood sampling during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute and relative (%) change in FEV1 percent predicted at 3, 7, 11, 15 and 28 weeks into the trial</measure>
    <time_frame>From baseline to 3, 7, 11, 15 and 28 weeks into the trial</time_frame>
    <description>Standardized, serial FEV1 measurements will be performed during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first protocol-defined pulmonary exacerbation</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>Reports of pulmonary exacerbation during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of protocol-defined pulmonary exacerbation</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>Reports of pulmonary exacerbation during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first change and usage of antibiotic (other than chronic inhaled antibiotics already started prior to trial or oral chronic azithromycin)</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>Reports of pulmonary exacerbation and their treatment during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline of systemic markers of inflammation in blood</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>This will be assessed through serial blood sampling during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from screening of the body weight and calculated Body Mass Index (BMI)</measure>
    <time_frame>From screening to 28 weeks</time_frame>
    <description>This will be assessed through serial weighing during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall change from screening of the Pseudomonas aeruginosa density (colony forming units) in the sputum</measure>
    <time_frame>From screening to Weeks 11 and 24</time_frame>
    <description>This will be assessed through induced sputum on 3 occasions during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The impact (from baseline) on overall health, daily life, perceived well-being and symptoms measured with the Cystic Fibrosis Questionnaire-Revised (CFQ-R)</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>This will be assessed through administration of the questionnaire at planned times during the trial</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in metabolipidomic profile and in markers of oxidative stress in blood</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>This will be assessed through serial blood sampling during the trial</description>
  </other_outcome>
  <other_outcome>
    <measure>The change in metabolipidomic profile in blood, the systemic markers of inflammation in blood, the FEV1, the body weight and calculated BMI</measure>
    <time_frame>From baseline to 28 weeks</time_frame>
    <description>Only in patients who experience a pulmonary exacerbation requiring intravenous antibiotics, this will be assessed prior to- and after the intravenous antibiotic course.</description>
  </other_outcome>
  <other_outcome>
    <measure>The change from baseline of systemic bone formation and resorption biomarkers</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>This will be assessed through blood sampling on 2 occasions during the trial</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>LAU-7b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug fenretinide (as LAU-7b capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule (as inactive capsules identical to active arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAU-7b</intervention_name>
    <description>LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.</description>
    <arm_group_label>LAU-7b</arm_group_label>
    <other_name>fenretinide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening FEV1 between 40% and 100% predicted value for age, gender and height, in
             patients capable of properly performing the test;

          -  History of pulmonary exacerbation, defined as at least one (1) pulmonary exacerbation
             in the year prior to Screening which resulted in documented intravenous or Oral
             antibiotics;

          -  Patients are eligible independently of their history of pulmonary Pseudomonas
             aeruginosa (PsA) infection and their PsA status at screening;

          -  If taking Kalydeco® (ivacaftor), Orkambi® (ivacaftor/lumacaftor), Symdeko®
             (ivacaftor/tezacaftor) or other commercially available CFTR modulator products,
             patients must be taking it for a minimum of 3 months prior to screening if naïve to
             CFTR modulators and 1 month if switched from another CFTR modulator product and deemed
             to tolerate it;

          -  No change in CF and allowed systemic chronic therapy for a minimum of 5 weeks prior to
             randomization, of which 2 weeks minimum are prior to screening;

          -  Female patients of child bearing potential should be on highly effective contraceptive
             methods during the study;

          -  Male patients with spouse or partner of child bearing potential, or pregnant, are
             eligible if they use an appropriate method of contraception.

        Exclusion Criteria:

          -  Pregnancy: due to the potential teratogenic effects of retinoids, pregnant women are
             NOT eligible;

          -  Breast milk feeding by study patient is NOT allowed;

          -  Clinically abnormal renal function: serum creatinine &gt; 132 μM (1.5 mg/dL);

          -  Clinically abnormal liver function: Total bilirubin &gt;1.5 x ULN (in the absence of
             demonstrated Gilbert's syndrome), alanine aminotransferase (ALT) and/or aspartate
             aminotransferase (AST) &gt; 2.5 x ULN;

          -  Patients with plasma retinol levels below 0.7 µM;

          -  Presence of nyctalopia or hemeralopia at enrolment, or any other serious retinal,
             ophthalmological condition;

          -  Presence of serious dermatological conditions at entry, including inflammatory or
             xerotic skin pathologies such as psoriasis or ichthyosis;

          -  Intake of chronic systemic steroids in the month prior to screening and during the
             study;

          -  History of acute infections (viral/bacterial/fungal) within 5 weeks prior to
             randomization, of which 2 weeks minimum are prior to screening, whether or not treated
             and resolved;

          -  Presence of infection with Burkholderia cepacia (including all species within the
             Burkholderia cepacia complex group, and Burkholderia gladioli) in the 12 months prior
             to screening;

          -  Patients with a confirmed diagnosis (as per the Cystic Fibrosis Foundation diagnostic
             criteria) of Allergic BronchoPulmonary Aspergillosis (ABPA) and actively being treated
             with corticosteroids and/or anti fungal agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry C Lands, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>McGill Uinversity Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael W Konstan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rainbow Babies and Children's Hospital/ University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Marie Houle, PhD</last_name>
    <phone>514-941-2313</phone>
    <email>jmhoule@laurentpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radu Pislariu, MD</last_name>
    <phone>514-513-2252</phone>
    <email>rpislariu@laurentpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Lee, CCRC</last_name>
      <phone>562-933-5609</phone>
    </contact>
    <contact_backup>
      <last_name>Candice Evans, CCRP</last_name>
      <phone>562-933-5607</phone>
    </contact_backup>
    <investigator>
      <last_name>Jimmy Johannes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Reyes, MSN ANP</last_name>
      <phone>323-361-2972</phone>
    </contact>
    <contact_backup>
      <last_name>Daniel Quevedo, RVN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thomas Keens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danieli Salinas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Selleck, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Reyes, MSN NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center, Division of Pulmonary &amp; Critical Care Medicine</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandt Robinson</last_name>
      <phone>916-734-8686</phone>
    </contact>
    <investigator>
      <last_name>Brian Morrissey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara L Purdy, CRA</last_name>
      <phone>202-476-6852</phone>
    </contact>
    <investigator>
      <last_name>Iman R Sami-Zakhari, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of pulmonary, critical care and sleep medicine, University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noni Graham, MPH CCRC</last_name>
      <phone>352-294-5195</phone>
    </contact>
    <investigator>
      <last_name>Cesar Trillo-Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System, Joe DiMaggio Children's Hospital Cystic Fibrosis &amp; Pulmonary Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma Jean Barton, MBBS MBA</last_name>
      <phone>954-265-4466</phone>
    </contact>
    <contact_backup>
      <last_name>Belkis Wandique, RN</last_name>
      <phone>954-265-3076</phone>
    </contact_backup>
    <investigator>
      <last_name>Lance Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avanza Medical Research Center</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Schindler, CRC</last_name>
    </contact>
    <contact_backup>
      <last_name>Michelle Schindler, CRC</last_name>
      <phone>850-477-7900</phone>
    </contact_backup>
    <investigator>
      <last_name>Luis C Murillo, MD FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St-Luke's CF Center of Idaho</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lejla Godusevic</last_name>
      <phone>208-381-4717</phone>
    </contact>
    <contact_backup>
      <last_name>Dixie Durham, RRT MHS</last_name>
      <phone>208-381-7334</phone>
    </contact_backup>
    <investigator>
      <last_name>Karen Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Shively, RN CPN CCRC</last_name>
    </contact>
    <contact_backup>
      <last_name>Lori A Shively, RN CPN CCRC</last_name>
      <phone>317-278-7121</phone>
    </contact_backup>
    <investigator>
      <last_name>James F Chmiel, MD MPH ATSF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence C Scott, BA, CCRC, LPN</last_name>
      <phone>913-588-4020</phone>
    </contact>
    <investigator>
      <last_name>Deepika Polineni, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center Cystic Fibrosis Research</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harmony Renna, CCRC</last_name>
      <phone>202-662-5917</phone>
    </contact>
    <contact_backup>
      <last_name>Amanda Cass, RT CCRC</last_name>
      <phone>207-662-6550</phone>
    </contact_backup>
    <investigator>
      <last_name>Jonathan B Zuckerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Kruse</last_name>
    </contact>
    <contact_backup>
      <last_name>Dawn Kruse</last_name>
      <phone>734-615-3266</phone>
    </contact_backup>
    <investigator>
      <last_name>Samya Nasr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University, Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra M Driscoll, RN</last_name>
      <phone>313-745-2221</phone>
    </contact>
    <contact_backup>
      <last_name>James Cahill, RN ANP-C</last_name>
      <phone>313-745-9537</phone>
    </contact_backup>
    <investigator>
      <last_name>Dana Kissner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zubin Mukadam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Minnesota Cystic Fibrosis Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Lynch, RRT</last_name>
      <phone>612-626-2743</phone>
    </contact>
    <investigator>
      <last_name>Joanne Billings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah P Smith, RN, BSN</last_name>
      <phone>314-454-5175</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey J Atkinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center, NJ Adult Cystic Fibrosis Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Connolly, RN</last_name>
      <phone>973-971-7293</phone>
    </contact>
    <investigator>
      <last_name>Rebecca A Griffith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University Clinical Research Center, RW Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Chen, RN</last_name>
      <phone>732-235-5965</phone>
    </contact>
    <contact_backup>
      <last_name>Lisa Cerracchio</last_name>
    </contact_backup>
    <investigator>
      <last_name>Sabiha Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DeNero, BSN</last_name>
      <phone>518-262-7851</phone>
    </contact>
    <contact_backup>
      <last_name>Cassandra Brady, LPN</last_name>
      <phone>518-262-5893</phone>
    </contact_backup>
    <investigator>
      <last_name>Thomas C Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Shaeffer</last_name>
    </contact>
    <contact_backup>
      <phone>216-286-0709</phone>
    </contact_backup>
    <investigator>
      <last_name>Erica A Roesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Johnson, RN BSN</last_name>
      <phone>614-722-4766</phone>
    </contact>
    <investigator>
      <last_name>Karen S McCoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Sanders</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>43053</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Kimberly Farley, LPN-RC</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>43049</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Nighat F Mehdi, MD FAAP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Center, Doernbecher Children's Hospital, Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Lento, CRC</last_name>
    </contact>
    <contact_backup>
      <last_name>Amy Chamberlain, MS</last_name>
      <phone>843-792-3162</phone>
    </contact_backup>
    <investigator>
      <last_name>Bryan Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Flume, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvia Szentpetery, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandie Taylor, APRN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Francis, B.S.</last_name>
      <phone>801-587-8105</phone>
    </contact>
    <investigator>
      <last_name>Theodore G Liou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Div of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine, John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabella Mackay, BSc</last_name>
      <phone>+61 2 4055 3051</phone>
    </contact>
    <investigator>
      <last_name>Peter Wark, BMed PhD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Taylor, BSN</last_name>
      <phone>+61 2 9515 8167</phone>
    </contact>
    <investigator>
      <last_name>Helen Jo, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Respiratory and Sleep Medicine, Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracey Burns, BSc</last_name>
      <phone>+61 2 8890 7785</phone>
    </contact>
    <investigator>
      <last_name>Peter G Middleton, MBBS BSc PhD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Ltd</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Martin, RN</last_name>
    </contact>
    <contact_backup>
      <last_name>Courtney Moloney, BA</last_name>
      <phone>+61 7 3163 2585</phone>
    </contact_backup>
    <investigator>
      <last_name>Lucy Burr, MBBS BSc PhD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Lung and Sleep, Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanne McKenzie, RN</last_name>
      <phone>+61 3 9594 2279</phone>
    </contact>
    <investigator>
      <last_name>Christopher P Daley, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolyn DeSylva, RN</last_name>
      <phone>+61 3 9076 5714</phone>
    </contact>
    <investigator>
      <last_name>Tom Kotsimbos, MD MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Respiratory Health, Harry Perkins Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meagan Shorten</last_name>
      <phone>+61 8 6151 0888</phone>
    </contact>
    <contact_backup>
      <last_name>Jessica Urquhart, BSN</last_name>
      <phone>+61 8 6151 0947</phone>
    </contact_backup>
    <investigator>
      <last_name>Anna Tai, MBChB PhD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Lung Research Institute at St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Kang, BS</last_name>
      <phone>604-806-8812</phone>
      <phone_ext>68812</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Eugenie Kwong</last_name>
      <phone>604-806-8117</phone>
    </contact_backup>
    <investigator>
      <last_name>Bradley Quon, MD MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jodi Goodwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Center for Practice-Changing Research</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Cassidy</last_name>
      <phone>613-737-8899</phone>
    </contact>
    <contact_backup>
      <last_name>Jency Jacob</last_name>
      <phone>613-737-8899</phone>
    </contact_backup>
    <investigator>
      <last_name>Shawn Aaron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'études cliniques CIUSS SLJ, Hôpital Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronick Tremblay</last_name>
      <phone>(418) 541-1000</phone>
      <phone_ext>2708</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Nancy-Lisa Gagné</last_name>
      <phone>(418) 541-1000</phone>
      <phone_ext>2707</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Christian Allard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Beaudoin, MSc RRT</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>14635</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Guillaume Coté-Maurais, MSc</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>14635</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>François Tremblay, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de recherche de l'institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Vadeboncoeur, RN, MSc</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3457</phone_ext>
    </contact>
    <investigator>
      <last_name>Lara Bilodeau, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Essential Fatty Acids</keyword>
  <keyword>Inflammation resolution</keyword>
  <keyword>Docosahexaenoic acid</keyword>
  <keyword>Lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

